Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) is anticipated to announce its Q1 2025 earnings results after the market closes on Monday, May 12th. Analysts expect Maravai LifeSciences to post earnings of ($0.07) per share and revenue of $44.01 million for the quarter.
Maravai LifeSciences Price Performance
Shares of NASDAQ MRVI traded up $0.08 during mid-day trading on Wednesday, reaching $2.12. The company had a trading volume of 884,199 shares, compared to its average volume of 2,349,857. The firm has a market cap of $537.92 million, a price-to-earnings ratio of -1.29 and a beta of 0.19. The business's 50-day simple moving average is $2.20 and its 200 day simple moving average is $4.32. Maravai LifeSciences has a one year low of $1.67 and a one year high of $11.56. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74.
Analyst Ratings Changes
Several analysts recently issued reports on MRVI shares. Baird R W lowered shares of Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. UBS Group decreased their price target on Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a research note on Friday, March 21st. Bank of America reduced their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Finally, Robert W. Baird cut shares of Maravai LifeSciences from an "outperform" rating to a "neutral" rating and lowered their price objective for the stock from $9.00 to $3.00 in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Maravai LifeSciences presently has an average rating of "Hold" and a consensus target price of $6.34.
Read Our Latest Stock Report on Maravai LifeSciences
Maravai LifeSciences Company Profile
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Read More
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
